Back to resultsClinical Study to Evaluate PRO-169 for Diabetic Macular Edema (PRO-169)
Primary Purpose
Diabetic Macular Edema
Status
Recruiting
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Bevacizumab
Lucentis®
Sponsored by
About this trial
This is an interventional treatment trial for Diabetic Macular Edema
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 18 years
- Diagnosis of Diabetes Mellitus (type 1 or 2) evidenced by: use of insulin or use of oral hypoglycemic medications or diagnosis for DM according to OMS or ADA criteria.
- Is capable of rendering informed consent.
- HbA1c <8.5% in selection visit.
- All men and women capable of reproduction may agree to use a barrier birth control method during the study and 3 months after the last intravitreal injection applied.
- Only one eye may be randomized per participating individual, in case both are eligible, the investigator may choose either eye according his/her criteria.
- BVCA according to ETDRS between <78 (20/32 or worse) and >24 (20/320 or better) within 8 days prior to the randomization.
- Clinically evident diabetic macular edema, with central macular thickening.
- Diabetic macular edema demonstrated in OCT scan (macular central thickness > 300 μm for men and > 290 μm for women) within 8 days prior to the randomization.
- Presenting characteristics that allow an adequate fundus examination (transparent means, adequate pupil dilation, etc).
Exclusion Criteria:
- Chronic renal disease with renal insufficiency that requires dialysis or transplant.
- Individuals with conditions that may compromise their participation during the span of the study (unstable concomitant diseases, possible change of residence, etc)
- Individuals with a poor glycemic control who have started insulin treatment within 4 months previous to the study.
- Participation in another clinical study (at least 90 days must have elapsed between the finalization of his/her participation in a previous essay and randomization in the present study).
- Known allergies to the treatment.
- Poorly controlled blood pressure (average of 3 readings while sitting with ≥160 mmHg systolic or ≥100 mmHg diastolic in the selection visit.
- Heart attack or other cardiovascular event (cerebral vascular disease, transitory ischemia, hospitalization for cardiac insufficiency) during the 4 months prior to the start of the study, or patients with active myocardial insufficiency.
- Previous systemic treatment with VEGF-related medications within 4 months prior to the start of the study.
- Women of child-bearing age who are pregnant, lactating of planning to get pregnant within the time span of the study.
- Known allergy to anesthetic medications used during the procedures, intravitreal injection and photocoagulation.
- Diagnosis of non-diabetic macular edema.
- Ophthalmic conditions that interfere with the evaluation of BCVA (for example: foveal atrophy, pigmentary abnormalities, dense foveal exudates, etc)
- Additional conditions to DM that may compromise the evaluation of the edema (for example: venous occlusions, uveitis or other inflammatory diseases, neovascular glaucoma, etc)
- Lens opacities that according to the LOCS III classification system exceed one or more of the following: > NO3C3, > C2, > P1.
- Previous history of anti-VEGF treatment for diabetic macular edema or any treatment for diabetic macular edema within 4 months prior to the start of the study (corticosteroids, photocoagulation, etc)
- Anticipation of the need of panphotocoagulation (for example: proliferative diabetic retinopathy or any other indication) during the period of the study or history of panphotocoagulation within the 4 months prior to the start of the study.
- History of ocular surgery (cataract extraction, any intraocular surgery, aphakia, etc) within 4 months prior to the start of the study, or planned to occur within the time span of the study.
- Intraocular pressure > 21 mmHg, measured through Goldmann tonometry during the selection visit.
- Presence of macular ischemia or important loss of perifoveal capilaries (avascular foveal zone greater than 350 μm) demonstrated through fluorescein angiography during the selection visit.
- Evidence of macular traction and hyaloid thickening in OCT scan.
- History of YAG capsulotomy within 2 months prior to the randomization.
- Evidence of external ocular infections or any important disease of the ocular surface.
- History of vitrectomy.
Sites / Locations
- Fundación Oftalmológica Nacional
- SalaUno Salud, S.A.P.I. de C.V.Recruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
PRO-169
Lucentis ®
Arm Description
Bevacizumab 1.25 mg / 0.05mL for intravitreal injection. All patients in this arm will be exposed to one monthly injection for the first four months. During the rest of the study, during the monthly visits, it will be decided if injections are to be continued or postponed. The maximum amount of intravitreal injections to be administered are 12.
Ranibizumab 0.5 mg / 0.05mL for intravitreal injection. All patients in this arm will be exposed to one monthly injection for the first four months. During the rest of the study, during the monthly visits, it will be decided if injections are to be continued or postponed. The maximum amount of intravitreal injections to be administered are 12.
Outcomes
Primary Outcome Measures
Best Corrected Visual Acuity
Best Corrected Visual Acuity will be evaluated according the standardized ETDRS. The mean change between two treatments will be used evaluated as difference between baseline and final (12 months) values.
Secondary Outcome Measures
Best Corrected Visual Acuity area under the curve
Best Corrected Visual Acuity will be evaluated according the standardized ETDRS. The area under the curve of both treatments will be used evaluated as difference between baseline and final (12 months) values.
Best Corrected Visual Acuity (adjusted to baseline)
Best Corrected Visual Acuity will be evaluated according the standardized ETDRS. The corrected BCVA (adjusted to baseline value) of both treatments will be used evaluated at 4 months.
Central Macular Thickness
Central macular thickness will be evaluated through OCT scan. The mean change between two treatments will be used evaluated as difference between baseline and final (12 months) values.
Retinal Volume
Retinal volume will be evaluated through OCT scan. The mean change between two treatments will be used evaluated as difference between baseline and final (12 months) values.
Percentage of patients with a positive response to treatment.
Determining the percentage of patients with a positive response to treatment, considered as: absolute improvement (20/20 vision for two consecutive visits and central macular thickness < 300 μm in men and < 290 μm in women), improvement (one or more of the following: patient who gained 5 or more letters for BCVA, ≥ 10% decrease of macular central thickness value compared to last two visits) and stability (one or more of the following: patient with neither a gain of 5 or more letters for BCVA nor a ≥ 10% decrease of macular central thickness value compared to last two visits, patient without loss of 5 or more letters for BCVA or a ≥ 10% decrease of macular central thickness value compared to last visit).
Mean number of injections
Determining the mean number of injections applied during study, comparing both arms.
Frequency of rescue therapy administration
Determining the frequency of the need of photocoagulation as a rescue therapy, comparing in both arms.
Adverse Events
Determining the incidence and severity of adverse events presented during the study, comparing both arms in both systemic and ophthalmic adverse events (related to research products).
Full Information
NCT ID
NCT05217680
First Posted
January 19, 2022
Last Updated
August 31, 2022
Sponsor
Laboratorios Sophia S.A de C.V.
1. Study Identification
Unique Protocol Identification Number
NCT05217680
Brief Title
Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema
Acronym
PRO-169
Official Title
Phase III Non-inferiority Clinical Study to Evaluate the Efficacy and Safety of Intravitreous PRO-169 Compared to Ranibizumab for Diabetic Macular Edema
Study Type
Interventional
2. Study Status
Record Verification Date
August 2022
Overall Recruitment Status
Recruiting
Study Start Date
May 17, 2021 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
December 31, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Laboratorios Sophia S.A de C.V.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Phase III clinical study to evaluate the efficacy, expressed as improvement in visual acuity in patients suffering diabetic macular edema after one year of treatment with PRO-169, compared to treatment with Lucentis® (ranibizumab).
Detailed Description
A total of 442 patients with diabetic macular edema will be randomized 1:1 to be treated with either PRO-169 (bevacizumab) or Lucentis® (ranibizumab). There will be a total of 14 visits, including selection and final visits. Monthly evaluations will include ophthalmologic evaluations of anterior and posterior segments, as well as OCT (optic coherence tomography) to obtain central macular width and retinal volume. Fluorescein angiography will be performed on selection visit as well as 6 and 12 months into the study (visits 7 and 13). All patients will be exposed to intravitreal injection of either of the studied drugs monthly for the first 4 months. Starting on visit 5 patients will be injected depending on their response to treatment, calculated according predetermined algorithms including clinical and image variables. Starting on month 6, patients may be subjected to rescue therapy with photocoagulation if they comply with predetermined criteria for such measure.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetic Macular Edema
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Clinical study, phase III, multi-centric, randomized, double-blind, with active parallel control to show non-inferiority.
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
442 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
PRO-169
Arm Type
Experimental
Arm Description
Bevacizumab 1.25 mg / 0.05mL for intravitreal injection. All patients in this arm will be exposed to one monthly injection for the first four months. During the rest of the study, during the monthly visits, it will be decided if injections are to be continued or postponed. The maximum amount of intravitreal injections to be administered are 12.
Arm Title
Lucentis ®
Arm Type
Active Comparator
Arm Description
Ranibizumab 0.5 mg / 0.05mL for intravitreal injection. All patients in this arm will be exposed to one monthly injection for the first four months. During the rest of the study, during the monthly visits, it will be decided if injections are to be continued or postponed. The maximum amount of intravitreal injections to be administered are 12.
Intervention Type
Biological
Intervention Name(s)
Bevacizumab
Intervention Description
Administration of monthly intravitreal bevacizumab (4-12 injections)
Intervention Type
Biological
Intervention Name(s)
Lucentis®
Intervention Description
Administration of monthly intravitreal ranibizumab (4-12 injections)
Primary Outcome Measure Information:
Title
Best Corrected Visual Acuity
Description
Best Corrected Visual Acuity will be evaluated according the standardized ETDRS. The mean change between two treatments will be used evaluated as difference between baseline and final (12 months) values.
Time Frame
Days: 0 (selection), 1 (randomization), 30±3 (Visit 2), 60±3 (Visit 3), 90±3 (Visit 4), 120±3 (Visit 5), 150±3 (Visit 6), 180±3 (Visit 7), 210±3 (Visit 8), 240±3 (Visit 9), 270±3 (Visit 10), 300±3 (Visit 11), 330±3 (Visit 12), 360±3 (Final Visit)
Secondary Outcome Measure Information:
Title
Best Corrected Visual Acuity area under the curve
Description
Best Corrected Visual Acuity will be evaluated according the standardized ETDRS. The area under the curve of both treatments will be used evaluated as difference between baseline and final (12 months) values.
Time Frame
Days: 0 (selection), 1 (randomization), 30±3 (Visit 2), 60±3 (Visit 3), 90±3 (Visit 4), 120±3 (Visit 5), 150±3 (Visit 6), 180±3 (Visit 7), 210±3 (Visit 8), 240±3 (Visit 9), 270±3 (Visit 10), 300±3 (Visit 11), 330±3 (Visit 12), 360±3 (Final Visit)
Title
Best Corrected Visual Acuity (adjusted to baseline)
Description
Best Corrected Visual Acuity will be evaluated according the standardized ETDRS. The corrected BCVA (adjusted to baseline value) of both treatments will be used evaluated at 4 months.
Time Frame
Days: 0 (selection), 1 (randomization), 30±3 (Visit 2), 60±3 (Visit 3), 90±3 (Visit 4), 120±3 (Visit 5)
Title
Central Macular Thickness
Description
Central macular thickness will be evaluated through OCT scan. The mean change between two treatments will be used evaluated as difference between baseline and final (12 months) values.
Time Frame
Days: 0 (selection), 1 (randomization), 30±3 (Visit 2), 60±3 (Visit 3), 90±3 (Visit 4), 120±3 (Visit 5), 150±3 (Visit 6), 180±3 (Visit 7), 210±3 (Visit 8), 240±3 (Visit 9), 270±3 (Visit 10), 300±3 (Visit 11), 330±3 (Visit 12), 360±3 (Final Visit)
Title
Retinal Volume
Description
Retinal volume will be evaluated through OCT scan. The mean change between two treatments will be used evaluated as difference between baseline and final (12 months) values.
Time Frame
Days: 0 (selection), 1 (randomization), 30±3 (Visit 2), 60±3 (Visit 3), 90±3 (Visit 4), 120±3 (Visit 5), 150±3 (Visit 6), 180±3 (Visit 7), 210±3 (Visit 8), 240±3 (Visit 9), 270±3 (Visit 10), 300±3 (Visit 11), 330±3 (Visit 12), 360±3 (Final Visit)
Title
Percentage of patients with a positive response to treatment.
Description
Determining the percentage of patients with a positive response to treatment, considered as: absolute improvement (20/20 vision for two consecutive visits and central macular thickness < 300 μm in men and < 290 μm in women), improvement (one or more of the following: patient who gained 5 or more letters for BCVA, ≥ 10% decrease of macular central thickness value compared to last two visits) and stability (one or more of the following: patient with neither a gain of 5 or more letters for BCVA nor a ≥ 10% decrease of macular central thickness value compared to last two visits, patient without loss of 5 or more letters for BCVA or a ≥ 10% decrease of macular central thickness value compared to last visit).
Time Frame
Days: 0 (selection), 1 (randomization), 30±3 (Visit 2), 60±3 (Visit 3), 90±3 (Visit 4), 120±3 (Visit 5), 150±3 (Visit 6), 180±3 (Visit 7), 210±3 (Visit 8), 240±3 (Visit 9), 270±3 (Visit 10), 300±3 (Visit 11), 330±3 (Visit 12), 360±3 (Final Visit)
Title
Mean number of injections
Description
Determining the mean number of injections applied during study, comparing both arms.
Time Frame
Days: 0 (selection), 1 (randomization), 30±3 (Visit 2), 60±3 (Visit 3), 90±3 (Visit 4), 120±3 (Visit 5), 150±3 (Visit 6), 180±3 (Visit 7), 210±3 (Visit 8), 240±3 (Visit 9), 270±3 (Visit 10), 300±3 (Visit 11), 330±3 (Visit 12), 360±3 (Final Visit)
Title
Frequency of rescue therapy administration
Description
Determining the frequency of the need of photocoagulation as a rescue therapy, comparing in both arms.
Time Frame
Days: 0 (selection), 1 (randomization), 30±3 (Visit 2), 60±3 (Visit 3), 90±3 (Visit 4), 120±3 (Visit 5), 150±3 (Visit 6), 180±3 (Visit 7), 210±3 (Visit 8), 240±3 (Visit 9), 270±3 (Visit 10), 300±3 (Visit 11), 330±3 (Visit 12), 360±3 (Final Visit)
Title
Adverse Events
Description
Determining the incidence and severity of adverse events presented during the study, comparing both arms in both systemic and ophthalmic adverse events (related to research products).
Time Frame
Days: 0 (selection), 1 (randomization), 30±3 (Visit 2), 60±3 (Visit 3), 90±3 (Visit 4), 120±3 (Visit 5), 150±3 (Visit 6), 180±3 (Visit 7), 210±3 (Visit 8), 240±3 (Visit 9), 270±3 (Visit 10), 300±3 (Visit 11), 330±3 (Visit 12), 360±3 (Final Visit)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age ≥ 18 years
Diagnosis of Diabetes Mellitus (type 1 or 2) evidenced by: use of insulin or use of oral hypoglycemic medications or diagnosis for DM according to OMS or ADA criteria.
Is capable of rendering informed consent.
HbA1c <8.5% in selection visit.
All men and women capable of reproduction may agree to use a barrier birth control method during the study and 3 months after the last intravitreal injection applied.
Only one eye may be randomized per participating individual, in case both are eligible, the investigator may choose either eye according his/her criteria.
BVCA according to ETDRS between <78 (20/32 or worse) and >24 (20/320 or better) within 8 days prior to the randomization.
Clinically evident diabetic macular edema, with central macular thickening.
Diabetic macular edema demonstrated in OCT scan (macular central thickness > 300 μm for men and > 290 μm for women) within 8 days prior to the randomization.
Presenting characteristics that allow an adequate fundus examination (transparent means, adequate pupil dilation, etc).
Exclusion Criteria:
Chronic renal disease with renal insufficiency that requires dialysis or transplant.
Individuals with conditions that may compromise their participation during the span of the study (unstable concomitant diseases, possible change of residence, etc)
Individuals with a poor glycemic control who have started insulin treatment within 4 months previous to the study.
Participation in another clinical study (at least 90 days must have elapsed between the finalization of his/her participation in a previous essay and randomization in the present study).
Known allergies to the treatment.
Poorly controlled blood pressure (average of 3 readings while sitting with ≥160 mmHg systolic or ≥100 mmHg diastolic in the selection visit.
Heart attack or other cardiovascular event (cerebral vascular disease, transitory ischemia, hospitalization for cardiac insufficiency) during the 4 months prior to the start of the study, or patients with active myocardial insufficiency.
Previous systemic treatment with VEGF-related medications within 4 months prior to the start of the study.
Women of child-bearing age who are pregnant, lactating of planning to get pregnant within the time span of the study.
Known allergy to anesthetic medications used during the procedures, intravitreal injection and photocoagulation.
Diagnosis of non-diabetic macular edema.
Ophthalmic conditions that interfere with the evaluation of BCVA (for example: foveal atrophy, pigmentary abnormalities, dense foveal exudates, etc)
Additional conditions to DM that may compromise the evaluation of the edema (for example: venous occlusions, uveitis or other inflammatory diseases, neovascular glaucoma, etc)
Lens opacities that according to the LOCS III classification system exceed one or more of the following: > NO3C3, > C2, > P1.
Previous history of anti-VEGF treatment for diabetic macular edema or any treatment for diabetic macular edema within 4 months prior to the start of the study (corticosteroids, photocoagulation, etc)
Anticipation of the need of panphotocoagulation (for example: proliferative diabetic retinopathy or any other indication) during the period of the study or history of panphotocoagulation within the 4 months prior to the start of the study.
History of ocular surgery (cataract extraction, any intraocular surgery, aphakia, etc) within 4 months prior to the start of the study, or planned to occur within the time span of the study.
Intraocular pressure > 21 mmHg, measured through Goldmann tonometry during the selection visit.
Presence of macular ischemia or important loss of perifoveal capilaries (avascular foveal zone greater than 350 μm) demonstrated through fluorescein angiography during the selection visit.
Evidence of macular traction and hyaloid thickening in OCT scan.
History of YAG capsulotomy within 2 months prior to the randomization.
Evidence of external ocular infections or any important disease of the ocular surface.
History of vitrectomy.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Alejandra Sanchez-Rios, MD
Phone
+52 33 3001 4200
Ext
1190
Email
alejandra.sanchez@sophia.com.mx
Facility Information:
Facility Name
Fundación Oftalmológica Nacional
City
Bogotá
Country
Colombia
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Juan P Rodriguez-Alvira, MD
Facility Name
SalaUno Salud, S.A.P.I. de C.V.
City
Ciudad de Mexico
ZIP/Postal Code
06030
Country
Mexico
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Claudia Palacio Pastrana, MD
Phone
+52155 5128 1140
First Name & Middle Initial & Last Name & Degree
MD
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema
We'll reach out to this number within 24 hrs